Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i>, anti-CD30-MCC-DM1 was found to be capable of inducing tumor regression in subcutaneous inoculation of Karpas 299 (anaplastic large cell lymphoma), HH (cutaneous T-cell lymphoma) and L428 (Hodgkin's disease) cell models.
|
31161871 |
2020 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas.
|
30841880 |
2019 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL.
|
31616638 |
2019 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hodgkin's lymphoma (HL) has a unique immunophenotype derived from immunohistochemistry (positive for CD15, CD30, and Pax-5; negative for CD3, CD20 in most cases, and CD45).
|
30350336 |
2019 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is expressed on a variety of B-cell lymphomas, such as Hodgkin lymphoma, primary effusion lymphoma, and a diffuse large B-cell lymphoma subgroup.
|
30962205 |
2019 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma.
|
30140037 |
2019 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
|
31476851 |
2019 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
|
29390984 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Following a wedge resection, histopathological examination showed Reed-Sternberg cells that were positive for CD-15 and CD-30, which is typical of HL.
|
29742695 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Their specific features and relationship to CD30-expressing Hodgkin and Reed/Sternberg (HRS) cells of Hodgkin lymphoma are unclear but highly relevant, because numerous patients with lymphoma are currently treated with an anti-CD30 immunotoxin.
|
29889102 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas broadly segregated into ALK-positive and ALK-negative types.
|
30093402 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is an anti-CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30-positive lymphomas, such as Hodgkin lymphoma and ALCL.
|
29806104 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is a Food and Drug Administration approved anti-CD30 antibody drug conjugate potently active in Hodgkin lymphoma.
|
29280762 |
2018 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL).
|
29316337 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin (BV) is a second-generation antibody-drug conjugate (ADC) constituted by an anti-CD30 antibody linked to the cytotoxic drug monomethyl auristatin E. The first administration of BV in relapsed and refractory HL patients in a phase I study showed an impressive antilymphoma activity and prompted development of the drug.
|
29999431 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
One patient, who was treated for PTLD, transformed to CD30+ Hodgkins disease, and was treated with brentuximab.
|
28708333 |
2017 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin's disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans.
|
28993768 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain.
|
28805662 |
2017 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Systemic anaplastic large cell lymphomas (sALCLs) comprise a heterogeneous group of relatively rare T-cell non-Hodgkin lymphomas that are characterized by CD30 expression.
|
28556361 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In tumor cells, CD30 expression is most commonly associated with lymphoid malignancies (Hodgkin and non-Hodgkin lymphomas) and is a therapeutic target using anti-CD30 antibody.
|
28521633 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context.234 CD30+ HL patients were enrolled.
|
29207679 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas that bear chromosomal rearrangements of the TP53 homologue TP63 in a subset of cases that demonstrate aggressive clinical behavior.
|
28153507 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).
|
28427526 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor T cells directed against CD30 have been investigated with preliminary clinical trials showing minimal toxicities and some responses in heavily pre-treated patients with HL.
|
28780614 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
|
28190142 |
2017 |